Study on Tear Proteins in Diabetic Retinopathy of Type 2 Diabetics
NCT ID: NCT00698698
Last Updated: 2009-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
350 participants
OBSERVATIONAL
2009-01-31
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fundus Findings and Thiol-Disulfide Homeostais
NCT05958927
Evaluation of Corneal Endothelial Changes After Uneventful Phacoemulsification in Diabetic and Non-diabetic Patients in Relation to the Level of Glcosylated Hemoglobin Level
NCT05426590
Corneal Endothelial Changes Associated With Phacoemulsification in Diabetes Mellitus Type II
NCT01078103
Evaluation of Progression of Diabetic Retinopathy With Rapid Correction of Hyperglycemia
NCT02326259
Integrating DR Into Mainstream Health System in Bangladesh
NCT03658980
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We can find different type of tear proteins in different grades of diabetic retinopathy these biomarkers can help in mass screening , diagnosis and management of diabetic population.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Non diabetic
Normal age and sex matched population
No interventions assigned to this group
Grade 1
Diabetic population with no retinopathy or Mild non proliferative diabetic retinopathy
No interventions assigned to this group
Grade 2
Moderate non proliferative diabetic retinopathy
No interventions assigned to this group
Grade 3
Severe non proliferative diabetic retinopathy
No interventions assigned to this group
Grade 4
Proliferative diabetic retinopathy and advanced diabetic eye disease
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age above 30
* willing to participate
Exclusion Criteria
* collagen vascular diseases
* Limbal hyperemia
* previous ocular surgery
* creatinine level above 1.0
* liver diseases
30 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dow University of Health Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dow university of Health Sciences Karachi Pakistan
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. Jamshed Ahmed, FCPS
Role: PRINCIPAL_INVESTIGATOR
Dow University of Health Sciences Pakistan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dow University of Health Sciences
Karachi, Sindh, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Tear proteins
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.